MERS antibodies produced in cattle safe, treatment well tolerated in phase 1 trial

(NIH/National Institute of Allergy and Infectious Diseases) An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial led by National Institutes of Health scientists and their colleagues. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news